Annovis Bio, Inc. announced on July 7, 2026, that its pivotal Phase 3 trial (NCT06709014) evaluating buntanetap for early Alzheimer's Disease (AD) has reached full enrollment of 850 patients with pTau217-confirmed AD pathology across 83 clinical sites in the United States. Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on neurodegenerative diseases.